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Abstract
Background: There is strong and consistent evidence that oxidative stress is crucially involved in
the development of atherosclerotic vascular disease. Overproduction of reactive oxygen species
(ROS) in mitochondria is an unifying mechanism that underlies micro- and macrovascular
atherosclerotic disease. Given the central role of mitochondria in energy and ROS production,
mitochondrial DNA (mtDNA) is an obvious candidate for genetic susceptibility studies on
atherosclerotic processes. We therefore examined the association between mtDNA haplogroups
and coronary artery disease (CAD) as well as diabetic retinopathy.
Methods:  This study of Middle European Caucasians included patients with angiographically
documented CAD (n = 487), subjects with type 2 diabetes mellitus with (n = 149) or without (n =
78) diabetic retinopathy and control subjects without clinical manifestations of atherosclerotic
disease (n = 1527). MtDNA haplotyping was performed using multiplex PCR and subsequent
multiplex primer extension analysis for determination of the major European haplogroups.
Haplogroup frequencies of patients were compared to those of control subjects without clinical
manifestations of atherosclerotic disease.
Results: Haplogroup T was significantly more prevalent among patients with CAD than among
control subjects (14.8% vs 8.3%; p = 0.002). In patients with type 2 diabetes, the presence of
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diabetic retinopathy was also significantly associated with a higher prevalence of haplogroup T
(12.1% vs 5.1%; p = 0.046).
Conclusion: Our data indicate that the mtDNA haplogroup T is associated with CAD and diabetic
retinopathy in Middle European Caucasian populations.
Background
Mitochondria are the primary source of endogenous reac-
tive oxygen species (ROS), generated through oxidative
phosphorylation (OXPHOS) as a by-product of ATP syn-
thesis. It is a generally accepted principle that in normal
cells, ROS form a regular part of diverse redox signalling
pathways, whereas in many types of chronic and cardio-
vascular diseases, ROS production exceeds antioxidant
capacity with damaging effects on cell function and struc-
ture [1]. Therefore, mitochondrial dysfunction has been
implicated in the pathogenesis of several diseases charac-
terised by free radical-induced damage. Given the central
role of mitochondria in energy and ROS production,
mitochondrial DNA (mtDNA) is an obvious candidate for
genetic susceptibility studies on atherosclerotic processes.
The extranuclear mitochondrial genome is highly poly-
morphic and this variation could contribute to the range
of complex traits in energy metabolism. Four of the enzy-
matic complexes that constitute the oxidative phosphor-
ylation system (OXPHOS) are partially encoded by the
mtDNA. Rare pathogenic mutations of the mtDNA, that
either impair mitochondrial protein synthesis or impair
proteins encoded by the mtDNA have been associated
with more than 70 human diseases [2].
During evolution, a number of mutations have accumu-
lated in the mtDNA [3]. Mutations acquired during evolu-
tion have subdivided the human population into a
number of discrete, region specific, mitochondrial clades
or haplogroups. MtDNA haplogroups are defined on the
basis of specific single nucleotide polymorphisms (SNPs)
scattered throughout the mitochondrial genome. In pop-
ulations of European ancestry, nine such haplogroups
with frequencies of at least 1% have been described [4].
Emerging evidence suggests that different mtDNA haplo-
groups are associated with subtle differences in OXPHOS
capacity and the generation of ROS [5,6]. Recent evidence
suggests that mtDNA haplogroups have functional conse-
quences, being linked to longevity [7], sperm motility [5],
certain types of cancer [8] and affecting the risk of individ-
uals developing specific late-onset neurodegenerative dis-
eases [9].
Diabetic retinopathy is caused by alterations in the retinal
microvasculature leading to breakdown of the blood-ret-
ina barrier and pathological angiogenesis [10] and is one
of the primary causes of visual loss worldwide [11]. Dia-
betic retinopathy and CAD are two vascular complications
of type 2 diabetes mellitus, representing examples of
microangiopathy and macroangiopathy, respectively.
Retinopathy is also an early and frequent sign of other vas-
cular complications and is strongly associated with the
development of CAD [12,13]. This indicates that CAD
and diabetic retinopathy share common risk factors and
pathological mechanisms, such as diabetes and inflam-
mation, which both exhibit increased ROS production
[14,15].
It has been shown that oxidative stress due to disturbance
in the balance between production of ROS and antioxi-
dant defence plays a vital role in the pathogenesis of cor-
onary atherosclerosis and its complications [15].
We aimed to investigate the association of mtDNA haplo-
groups with CAD as well as diabetic retinopathy.
Methods
Patients and control subjects
Data from 2352 Caucasian subjects enrolled in three sur-
veys in central and southern Austria were analysed (Table
1). The study was conducted according to the Austrian
Gene Technology Act and complied with the Declaration
of Helsinki. All subjects gave written informed consent
before entering the study.
Patients with heart diseases (n = 598) were recruited in
Salzburg and Graz. Four hundred and eighty-seven indi-
viduals had angiographically documented CAD with at
least one of the main coronary arteries showing ≥ 50% ste-
nosis. CAD was angiographically excluded in 111 patients
with valvular heart disease.
The study population of patients with diabetes (n = 227)
was recruited at the University Hospital of Graz and con-
sisted of patients with (n = 149) and without diabetic
retinopathy (n = 78). Presence and severity of diabetic
retinopathy were assessed by fundus examination. Dia-
betic retinopathy was graded according to the modified
"Early Treatment Diabetic Retinopathy Study" (ETDRS)
retinopathy scale as no apparent retinopathy, non-prolif-
erative, and proliferative diabetic retinopathy.
The control population consisted of 1527 unrelated indi-
viduals as previously described in detail [16]. Briefly, the
cohort comprised 988 men between 39 and 66 years of
age and 539 women between 39 and 67 years of age whoBMC Medical Genetics 2009, 10:35 http://www.biomedcentral.com/1471-2350/10/35
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were recruited in the Salzburg Atherosclerosis Prevention
Program (SAPHIR) [16]. Exclusion criteria for participa-
tion in this study were a history of CAD, heart failure, cer-
ebrovascular disease, peripheral vascular disease,
haemodynamically relevant heart valve disease, chronic
disease (of liver or kidney, autoimmune disorders, malig-
nant cancer, haematologic disorders, endocrinopathies,
diabetes mellitus) and morbid obesity. Laboratory meth-
ods have been described previously [16]. The haplogroup
frequency in 1172 individuals of the control cohort was
reported [17]. The study was approved by the Ethics Com-
mittee of the Medical Association of Salzburg.
MtDNA analysis
Venous blood was collected in 5 ml EDTA tubes; total
DNA was isolated with a Nucleospin Blood Kit (Mach-
erey-Nagel) and stored at 4°C. A hierarchical system for
mtDNA haplogrouping that combines multiplex PCR
amplifications, multiplex single-base primer extensions,
and capillary-based electrophoretic separation for analys-
ing ten haplogroup-diagnostic mitochondrial SNPs
(mtSNPs) was used to determine the haplogroup distribu-
tion of the most common European haplogroups H, U, J,
T, K, I, V, W and X, as described previously [17]. Haplo-
groups that could not be assigned to one of the nine major
European haplogroups by the SNP combination were des-
ignated as "others". From the 2387 subjects investigated,
genotyping failed in 0.21% of the samples (n = 5). PCR
amplification failed due to degradation of DNA in 1.26%
of samples (n = 30).
Statistical analysis
Frequencies of all mitochondrial haplogroups in CAD
patients and in controls were tested for independency
using Pearson chi-square statistics and Fisher's exact test as
appropriate. Similarly, frequencies of mitochondrial hap-
logroups were compared between patients with heart dis-
ease other than CAD and controls. For further analysis
only low frequency haplogroups (K, W, V, I, X) were
excluded from further analyses. Age and gender adjusted
odds ratios and 95% confidence intervals were then calcu-
lated to express the strength of the associations between
the haplogroups and phenotypes. The following variables
were also considered as potential confounders and tested
in logistic regression models: hypertension (yes/no),
body mass index (BMI), and smoking (never, former
smoker, current smoker). Covariates that had a signifi-
cance level of less than 0.1 were retained to create the best-
fitting model based on Akaike's information criterion. If
one category of an independent variable had a signifi-
cance of 0.1 or less, all parts of the categorical variable
were retained in the best-fitting model. P-values were cor-
rected for multiple comparison by Bonferroni analysis
(required significance level = 0.05/number of compari-
sons), leading to a new required significance level of
<0.008 [number of comparisons = 6 (3 × 2) for 3 haplo-
groups compared to haplogroup H and to two diseases
(CAD and Valvular Heart Disease)].
The same methods as described above were applied to cal-
culate associations between mitochondrial haplogroups
and the presence of retinopathy among patients with dia-
betes. Sex-adjusted odds ratios and 95% confidence inter-
vals were then tested for the potential confounding effect
of age at onset of diabetes (years), duration of diabetes
(months), levels of HbA1c (%) measured at the time of
recruitment, medication (insulin, oral antidiabetics), his-
tory of myocardial infarction (yes/no), and hypertension
(yes/no). The best-fitting model was created in the same
manner as for the heart disease population. P-values were
corrected for multiple comparison by Bonferroni analysis
(required significance level = 0.05/number of compari-
sons), leading to a new required significance level of
<0.017 (number of comparisons = 3 for 3 haplogroups
compared to haplogroup H).
All analyses were performed using SPSS 15.0 student ver-
sion (SPSS GmbH Software, 80339 Munich, Germany)
Table 1: Characteristics of the study populations.
Controls Patients with heart disease Patients with diabetes
CAD Valvular Heart Disease No Retinopathy Retinopathy
n = 1527 n = 487 n = 111 n = 78 n = 149
Mean (SD*) age (years) 51.5 (6.1) 63.4 (11.3) 64.9 (12.9) 76.9 (9.8) 71.1 (11.2)
Male (%) 64.7 76.4 54.1 47.4 36.9
Mean (SD*) BMI† (kg/m2) 26.6 (4.1) 27.3 (3.7) 26.3 (4.5) 27.5 (4.5) 27.7 (5.3)
History of myocardial infarction (%) 0 50.5 0 7.7 14.8
Diagnosis of diabetes (%) 0 25.5 16.2 100 100
Hypertension (%) 13.7 67.6 59.5 75.6 71.8
Nonsmoker (%) 65.3 48.7 72.4 n.a.‡ n.a.‡
Former smoker (%) 13.5 37.5 14.3 n.a.‡ n.a.‡
Current smoker (%) 21.2 13.8 13.3 n.a.‡ n.a.‡
*SD: standard deviation; †BMI: body mass index;‡n.a. = not available.BMC Medical Genetics 2009, 10:35 http://www.biomedcentral.com/1471-2350/10/35
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and Stata/SE 10.0 (Stata Corporation, College Station, TX,
USA).
Results
Clinical characteristics of patients and controls are shown
in Table 1. All nine European haplogroups were observed
in our sample, as expected (Table 2). Frequencies in the
control group did not differ significantly from those pre-
viously reported for neighbouring European Caucasian
populations [17,18].
Frequencies of mitochondrial haplogroups in patients
with CAD differed significantly from those in healthy con-
trols. The frequency of haplogroup T in controls was 8.3%
and in patients with CAD 14.8%. After adjustment for sex
and age we calculated an OR (95% CI) of 2.36 (1.52–
3.65) for the association of haplogroup T with CAD. Fur-
ther adjustment for possible confounders revealed that
the strong association between haplogroup T and CAD
was not explained by differences in age, sex, hypertension,
body mass index, or smoking status (Table 3). Even after
adjustment for multiple comparisons by Bonferroni cor-
rection the p-value remained significant. None of the
other haplogroups showed a significant association with
CAD (Table 3). Haplogroup frequencies were very similar
in the two study centres, Salzburg and Graz. Nearly iden-
tical associations were seen when the analyses were strati-
fied according to the two study centres from which the
patients had been recruited. The age- and sex-adjusted OR
(95% CI) for the association between CAD and mitochon-
drial haplogroup T was significant in patients recruited in
Graz [n = 195; OR 2.22 (1.36–3.63); p = 0.001] and those
recruited in Salzburg [n = 292; OR 2.36 (1.14–4.88); p =
0.021]. In contrast, no difference in the frequencies of
mitochondrial haplogroups was seen between patients
with valvular heart disease with documented absence of
CAD and healthy controls (Table 3).
We next compared the frequencies of the mitochondrial
haplogroups between patients with diabetes with retinop-
athy and patients with diabetes without retinopathy. Hap-
logroup T was significantly more prevalent in patients
with diabetic retinopathy than in patients without that
condition (12.1% vs 5.1%; Tables 2, 4). There was a posi-
tive association between haplogroup T and retinopathy
among patients with diabetes, which became significant
when the best-fitting model was created (Table 4). After
adjustment for multiple comparisons by Bonferroni cor-
rection the association was no longer significant, most
likely due to the small sample size. Subgroup analysis
revealed no significant differences in DNA haplogroups
between patients with and without proliferative diabetic
retinopathy (n = 75; Pearson chi-square 3.4, df4, p =
0.493). Also, no trend of haplogroup T with severity of
retinopathy was observed as can be derived from the fre-
quencies of haplogroup T in non-proliferative retinopathy
(13.3%) and proliferative retinopathy (10.8%).
Discussion
Our data show an association of mtDNA haplogroup T
with coronary artery disease and diabetic retinopathy.
Mitochondrial dysfunction has been implicated in the
pathogenesis of several diseases characterised by free rad-
ical-induced damage [19-21]. Genetic association of spe-
cific mtDNA haplogroups has been demonstrated with
aging and multifactorial age-related diseases like Alzhe-
imer's disease, multiple sclerosis and cancer [22].
Although the precise mechanisms underlying the associa-
tions of mtDNA haplogroups with multifactorial age-
related diseases including CAD and diabetic retinopathy
remain speculative, haplogroup-specific differences in
free radical production during OXPHOS may be one such
mechanism. Thus, presence of haplogroup T might be
associated with increased oxidative stress or increased sus-
ceptibility to oxidative stress. Individuals carrying haplo-
group T might be more vulnerable to oxidative damage
than carriers of other haplogroups.
While intracellular ROS serve mainly for host defence
against infectious agents, redox-sensitive signal transduc-
Table 2: Frequencies (%) of mitochondrial haplogroups in cases and controls.
Haplogroup Controls Patients with heart diseases Patients with diabetes
CAD Valvular Heart Disease No Retinopathy Retinopathy
n = 1527 n = 487 n = 111 n = 78 n = 149
H 43.6 37.8 46.0 52.5 43.6
U 15.5 15.0 16.2 11.5 14.8
J 11.4 10.9 12.6 5.1 10.7
T 8.3 14.8 9.0 5.1 12.1
K 5.2 3.1 0.9 3.9 3.4
W 2.1 1.8 1.8 0.0 2.0
V 1.8 3.1 0.9 2.6 2.0
I 1.0 1.2 1.8 1.3 0.7
X 1.3 3.1 1.8 3.9 2.0
others 9.8 9.2 9.0 14.1 8.7BMC Medical Genetics 2009, 10:35 http://www.biomedcentral.com/1471-2350/10/35
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tion, and other cellular processes, the extracellular release
of ROS may damage surrounding tissues, potentially pro-
moting inflammatory processes [23,24]. ROS are involved
in aging and many diseases such as atherosclerosis, can-
cer, diabetes mellitus, neurological degeneration, and
tumor invasion. There is strong evidence that inflamma-
tion also plays a major role in the etiology and progres-
sion of diabetic retinopathy [14]. Inflammation is an
integral part not only of CAD but also of other complex
diseases like multiple sclerosis, where an association of
mtDNA haplogroups has been reported [25]. Enhanced
formation of ROS may affect four fundamental mecha-
nisms that contribute to atherogenesis, namely: oxidation
of low density lipoprotein (LDL), endothelial dysfunc-
tion, vascular smooth muscle cell growth, and monocyte
migration [21]. Interestingly, we did not find an associa-
tion of haplogroup T to markers of inflammation like C-
reactive protein (CRP) and LDL (data not shown).
Previous exact analysis of specific differences in the
mtDNA haplogroups revealed that haplogroup T is gener-
ally associated with a number of polymorphisms in the
non-coding control region (16126, 16294), mitochon-
drial ribosomal RNAs (709, 1888), mitochondrial transfer
RNAs (10463, 15928), several SNPs not changing amino
acids in the corresponding proteins, and a polymorphism
at position 4917 leading to a change of asparagin to aspar-
tate in the ND2 protein [26]. All these SNPs could contrib-
ute to altered OXPHOS performance and ROS
production. This hypothesis was substantiated by Ruiz-
Pesini et al., who have shown that sperm cells of individ-
uals with haplogroup T have a lower activity of respiratory
chain complexes than sperm cells with haplogroup H [5].
In contrast, another study was not able to demonstrate
bioenergetic differences of isogenetic cell lines represent-
ing haplogroup H and T [27]. Unfortunately alteration of
ROS production in these cell lines with different haplo-
groups has not been reported. We assume that the differ-
ences in ROS production among the haplogroups are
subtle, requiring both time and interactions with other
genetic and environmental factors before pathological
manifestation. In accordance with previous studies, we
found no association between mtDNA haplogroups and
type 2 diabetes mellitus when all patients with diabetes
(with and without retinopathy) were included [28]. Epi-
demiological studies in Japan showed an association of a
mtDNA variation (position 5178, haplogroup N9b) with
myocardial infarction [29,30]. We did not investigate the
mtDNA variant located at position 5178, which is an indi-
cator for Asian haplogroup D and the N9b haplogroup,
because these variations are not prevalent in European
Caucasians. Our data, however, support the concept that
mtDNA variability is associated with vascular diseases.
A recent study from Denmark found no association of
mtDNA haplogroups with ischemic cardiovascular dis-
ease, cancer, infectious diseases, longevity and mortality
in a general population of northern European descent
[31]. The study was perspective, included a large number
of individuals with a long follow up. No major associa-
tion to a wide variety of diseases was observed, although
Table 3: Odds ratios (OR) and 95% confidence intervals (CI) for the association between mitochondrial haplogroup and CAD and 
Valvular Heart Disease, respectively.
Haplogroup OR* (95% CI) p-value aOR† (95% CI) p-value
Coronary artery disease
H 1 (ref) 1 (ref)
U 1.06 (0.69–1.61) 0.791 1.18 (0.72–1.93) 0.504
J 0.92 (0.58–1.47) 0.738 1.09 (0.63–1.89) 0.766
T 2.36 (1.52–3.65) < 0.0005‡ 2.33 (1.37–3.98) 0.002‡
Valvular Heart disease
H 1 (ref)
U 1.05 (0.50–2.17) 0.903
J 0.96 (0.44–2.14) 0.930
T 1.24 (0.52–2.96) 0.626
*Adjusted for age and sex (CAD n = 382, Valvular heart disease n = 93, controls n = 1203); †adjusted for age, sex, smoking, hypertension, and body 
mass index (CAD n = 345, controls n = 1095); ‡Bonferroni-corrected statistical significance: p < 0.05/3 × 2 = < 0.008.
Table 4: Odds ratios (OR) and 95% confidence intervals (CI) for 
the association between mitochondrial haplogroup and 
retinopathy in patients with diabetes (n = 179).
Haplogroup OR* (95% CI) p-value aOR† (95% CI) p-value
H 1 (ref) 1 (ref)
U 1.54 (0.64–3.69) 0.330 1.92 (0.72–5.07) 0.190
J 2.59 (0.81–8.34) 0.110 2.04 (0.50–8.36) 0.324
T 2.97 (0.93–9.48) 0.065 3.60 (1.02–12.68) 0.046‡
*Adjusted for sex; †adjusted for sex, history of myocardial infarction, 
levels of HbA1c and therapy with oral antidiabetics; ‡Bonferroni-
corrected statistical significance p < 0.05/3 = < 0.017.BMC Medical Genetics 2009, 10:35 http://www.biomedcentral.com/1471-2350/10/35
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there is a vast literature on the association of mtDNA hap-
logroups with several diseases available. One explanation
could be the different geographical distribution of
mtDNA haplogroups. Therefore, our study on a middle
European population can not be directly compared with
the Danish study. Furthermore, Benn et al. investigated
cases with myocardial infarction or symptoms considered
characteristic of angina pectoris whereas in our study we
included patients with angiographically documented
CAD (i.e. ≥ 50% stenosis of at least one of the major epi-
cadial vessels) – a criteria consistently used in the litera-
ture defining clinically relevant CAD [32,33].
We assume that a certain percentage of our control sub-
jects will develop CAD and/or diabetes. This might have
led to an underestimation of the effects we observed in the
present study. If these persons could have been excluded,
then one could expect that the prevalence of haplogroup
T would have been even lower than was observed in the
present control cohort; this in turn would increase the sta-
tistical significance of our findings. When we performed
statistical analysis of CAD patients with a similar mean of
age as controls, we found that there was an even larger dif-
ference in frequencies of haplogroup T between cases and
controls (data not shown). We can not exclude that other
unknown and unmeasured confounding factors are
present.
Conclusion
In the present study, mitochondrial haplogroup T is sig-
nificantly associated with the presence of CAD and dia-
betic retinopathy, indicating that the presence of
haplogroup T contributes to the risk of developing both
CAD and diabetic retinopathy. The association between
vascular disease and haplogroup variation of mtDNA, as
demonstrated in the present study, should stimulate fur-
ther investigation on their biological effects as well as on
their relations to chronic diseases.
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